Atherosclerosis Supplements
-
Publication Venue For
- EFFICACY AND SAFETY OF EZETIMIBE/SIMVASTATIN COADMINISTERED WITH EXTENDED RELEASE NIACIN IN PATIENTS WITH TYPE IIA OR IIB HYPERLIPIDEMIA. 9:16-16. 2008
- SAFETY AND TOLERABILITY OF THE TRIPLE COMBINATION EZETIMIBE/SIMVASTATIN + EXTENDED RELEASE NIACIN IN HYPERLIPIDEMIA PATIENTS. 9:261-261. 2008
- TIME AND DOSE-RELATED EFFECTS ON THE LIPID PROFILE IN HYPERLIPIDEMIA PATIENTS FOLLOWING TRIPLE COMBINATION THERAPY WITH EZETIMIBE/SIMVASTATIN + NIACIN. 9:186-187. 2008
- Lp(a) and Cardiovascular Outcomes: an Analysis from the ODYSSEY OUTCOMES Trial 2018
- 59 RELATIONSHIPS BETWEEN HSCRP REDUCTION AND LDL-C, NONHDL-C, APOB AND HDL-C IN HYPERLIPIDEMIC PATIENTS TREATED WITH EZETIMIBE/SIMVASTATIN + EXTENDED-RELEASE NIACIN 2011
- 781 MORE AGGRESSIVE LDL-C AND NON-HDL-C TARGETS MUST BE ACHIEVED IN PATIENTS RECEIVING LIPID-LOWERING THERAPY TO NORMALIZE APOB-CONTAINING LIPOPROTEINS 2011
- 82 COMBINATION EZETIMIBE/SIMVASTATIN + EXTENDED-RELEASE NIACIN THERAPY IMPROVES ATTAINMENT OF RECOMMENDED LDL-C, NON-HDL-C AND APOB LEVELS IN HYPERLIPIDEMIC PATIENTS 2011
- PO23-734 INFLUENCE OF AGE, GENDER, AND ETHNICITY ON TREATMENT EFFECTS IN THE VYTAL TRIAL OF EZETIMIBE/SIMVASTATIN VS. ATORVASTATIN IN TYPE 2 DIABETICS 2007
- PO23-755 EZETIMIBE/SIMVASTATIN MORE FAVORABLY INFLUENCES LIPOPROTEIN/APOLIPOPROTEIN RATIOS THAN ATORVASTATIN MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES 2007
- PO23-777 EFFECT OF EZETIMIBE/SIMVASTATIN VERSUS ATORVASTATIN ON ATTAINING RECOMMENDED LEVELS OF LDL-C, APOLIOPROTEIN B, NON-HDL-C AND HS-CRP IN TYPE 2 DIABETES 2007
- PO23-786 ASSOCIATION BETWEEN BASELINE LDL-C, TRIGLYCERIDES, AND HDL-C LEVELS AND THE LIPID-ALTERING AND HS-CRP EFFICACIES OF EZETIMIBE/SIMVASTATIN VERSUS ATORVASTATIN IN TYPE 2 DIABETES PATIENTS: THE VYTAL STUDY 2007
- Su-S1:2 The neurological system and statin safety 2006